RxDoctor Payments Data

Sherri Schwartz, MD

Family Medicine · Newport, KYNPI 1093976375

Payments from drug & device makers

$746in general payments, 2019–2025

Across 47 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$190
  • Lilly USA, LLC$109
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
  • Novo Nordisk$85
  • Astellas Pharma US Inc$63
  • AstraZeneca$49
  • plus $158 from 9 others

What the payments were for

  • Food & beverage$68392%
  • Education$638%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$746 in reported general payments places this provider in the 50th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$52,158
Medicare patients
176
Services billed
3,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$75,754
EliquisApixaban96$65,392
MounjaroTirzepatide47$53,256
TrulicityDulaglutide31$51,268
JardianceEmpagliflozin38$46,657
XareltoRivaroxaban35$39,248
JanuviaSitagliptin Phosphate32$24,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,750
LinzessLinaclotide15$12,504
Spiriva HandihalerTiotropium Bromide11$10,447
SymbicortBudesonide/Formoterol Fumarate24$10,287
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$6,162
Breo ElliptaFluticasone/Vilanterol15$5,768
Arnuity ElliptaFluticasone Furoate15$4,627
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$109$104,52578 claims
Novo NordiskOzempic$85$75,75449 claims
PfizerEliquis$12$65,39296 claims
Boehringer IngelheimJardiance$13$46,65738 claims
MerckJanuvia$12$24,40732 claims
AbbVieLinzess$190$12,50415 claims
AstraZenecaSymbicort$49$10,28724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Newport

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →